Literature DB >> 25390262

Cytomegalovirus disease in immunocompetent adults.

Daniel Lancini1, Helen M Faddy2, Robert Flower2, Chris Hogan2.   

Abstract

Cytomegalovirus (CMV) is a highly prevalent and globally distributed virus. CMV infection in healthy adults is usually asymptomatic or causes a mild mononucleosis-like syndrome. CMV disease causes significant morbidity and mortality in neonates and severely immunocompromised adults. CMV disease can present with a wide range of manifestations, with colitis being the most common. The incidence of severe CMV disease in immunocompetent adults appears to be greater than previously thought, which may be partly due to immune dysfunction related to comorbidities such as kidney disease or diabetes mellitus. CMV disease can mimic an array of alternative diagnoses and pose a significant diagnostic challenge, especially in immunocompetent adults, leading to delayed diagnosis, adverse health outcomes and unnecessary financial expense. Non-invasive testing for CMV is widely available and can facilitate early diagnosis if used appropriately. Although limited, current evidence suggests that targeted antiviral therapy with ganciclovir or valganciclovir is appropriate for severe CMV disease in immunocompetent adults.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25390262     DOI: 10.5694/mja14.00183

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  34 in total

1.  Cytomegalovirus colitis mimicking rectal carcinoma in an immunocompetent elderly woman.

Authors:  Elena Chidlovskii; Alban Deroux; Sylvain Bernard; Pascal Couturier
Journal:  BMJ Case Rep       Date:  2016-05-10

2.  Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences.

Authors:  Hiroshi Nakase; Hans Herfarth
Journal:  Inflamm Intest Dis       Date:  2016-01-23

Review 3.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

4.  Cytomegalovirus Disease of the Upper Gastrointestinal Tract: An Emerging Infection in Immunocompetent Hosts.

Authors:  Elisa Gravito-Soares; Nuno Almeida
Journal:  GE Port J Gastroenterol       Date:  2017-08-31

5.  Cytomegalovirus ulcerative oesophagitis in a young healthy immunocompetent patient.

Authors:  Elisa Gravito-Soares; Marta Gravito-Soares; Ernestina Camacho; Luis Tomé
Journal:  BMJ Case Rep       Date:  2018-03-05

6.  Seroepidemiology of cytomegalovirus infections in Croatia.

Authors:  Tatjana Vilibic-Cavlek; Branko Kolaric; Natasa Beader; Izabela Vrtar; Irena Tabain; Gordana Mlinaric-Galinovic
Journal:  Wien Klin Wochenschr       Date:  2016-09-06       Impact factor: 1.704

7.  Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.

Authors:  Raphaëlle Riou; Céline Bressollette-Bodin; David Boutoille; Katia Gagne; Audrey Rodallec; Maeva Lefebvre; François Raffi; David Senitzer; Berthe-Marie Imbert-Marcille; Christelle Retière
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

8.  Cytomegalovirus-Induced Pericarditis, Pulmonary Embolism, and Transaminitis in an Immunocompetent Patient.

Authors:  Waiz Wasey; Navpreet Badesha; Maria Rossi; Caitlin Carter; Samantha Bibee
Journal:  Cureus       Date:  2021-11-05

9.  Challenges of Primary Care Medicine in a Tertiary Care Setting-The Case of Primary CMV Infection Compared to Primary EBV Infection: A Retrospective Cohort Study.

Authors:  Samuel Etienne; Karoline Leuzinger; Hans H Hirsch; Michael Osthoff
Journal:  Front Med (Lausanne)       Date:  2022-06-14

Review 10.  CMV-Specific Cell-Mediated Immunity in Immunocompetent Adults with Primary CMV Infection: A Case Series and Review of the Literature.

Authors:  Angela Chiereghin; Gabriella Verucchi; Tiziana Lazzarotto
Journal:  Viruses       Date:  2021-05-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.